Cargando…

Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation

Regulatory T cells (Tregs) constitute a small proportion of circulating CD4(+) T cells that function to maintain homeostasis and prevent autoimmunity. In light of their powerful immunosuppressive and tolerance-promoting properties, Tregs have become an interesting potential candidate for therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Dudreuilh, Caroline, Basu, Sumoyee, Scottà, Cristiano, Dorling, Anthony, Lombardi, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884443/
https://www.ncbi.nlm.nih.gov/pubmed/33603742
http://dx.doi.org/10.3389/fimmu.2020.612848
_version_ 1783651417940033536
author Dudreuilh, Caroline
Basu, Sumoyee
Scottà, Cristiano
Dorling, Anthony
Lombardi, Giovanna
author_facet Dudreuilh, Caroline
Basu, Sumoyee
Scottà, Cristiano
Dorling, Anthony
Lombardi, Giovanna
author_sort Dudreuilh, Caroline
collection PubMed
description Regulatory T cells (Tregs) constitute a small proportion of circulating CD4(+) T cells that function to maintain homeostasis and prevent autoimmunity. In light of their powerful immunosuppressive and tolerance-promoting properties, Tregs have become an interesting potential candidate for therapeutic use in conditions such as solid organ transplant or to treat autoimmune and inflammatory conditions. Clinical studies have demonstrated the safety of polyclonally expanded Tregs in graft-versus-host disease, type 1 diabetes, and more recently in renal and liver transplantation. However, Tregs are heterogenous. Recent insights indicate that only a small proportion of Tregs, called T follicular regulatory cells (Tfr) regulate interactions between B cells and T follicular helper (Tfh) cells within the germinal center. Tfr have been mainly described in mouse models due to the challenges of sampling secondary lymphoid organs in humans. However, emerging human studies, characterize Tfr as being CD4(+)CD25(+)FOXP3(+)CXCR5(+) cells with different levels of PD-1 and ICOS expression depending on their localization, in the blood or the germinal center. The exact role they play in transplantation remains to be elucidated. However, given the potential ability of these cells to modulate antibody responses to allo-antigens, there is great interest in exploring translational applications in situations where B cell responses need to be regulated. Here, we review the current knowledge of Tfr and the role they play focusing on human diseases and transplantation. We also discuss the potential future applications of Tfr therapy in transplantation and examine the evidence for a role of Tfr in antibody production, acute and chronic rejection and tertiary lymphoid organs. Furthermore, the potential impact of immunosuppression on Tfr will be explored. Based on preclinical research, we will analyse the rationale of Tfr therapy in solid organ transplantation and summarize the different challenges to be overcome before Tfr therapy can be implemented into clinical practice.
format Online
Article
Text
id pubmed-7884443
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78844432021-02-17 Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation Dudreuilh, Caroline Basu, Sumoyee Scottà, Cristiano Dorling, Anthony Lombardi, Giovanna Front Immunol Immunology Regulatory T cells (Tregs) constitute a small proportion of circulating CD4(+) T cells that function to maintain homeostasis and prevent autoimmunity. In light of their powerful immunosuppressive and tolerance-promoting properties, Tregs have become an interesting potential candidate for therapeutic use in conditions such as solid organ transplant or to treat autoimmune and inflammatory conditions. Clinical studies have demonstrated the safety of polyclonally expanded Tregs in graft-versus-host disease, type 1 diabetes, and more recently in renal and liver transplantation. However, Tregs are heterogenous. Recent insights indicate that only a small proportion of Tregs, called T follicular regulatory cells (Tfr) regulate interactions between B cells and T follicular helper (Tfh) cells within the germinal center. Tfr have been mainly described in mouse models due to the challenges of sampling secondary lymphoid organs in humans. However, emerging human studies, characterize Tfr as being CD4(+)CD25(+)FOXP3(+)CXCR5(+) cells with different levels of PD-1 and ICOS expression depending on their localization, in the blood or the germinal center. The exact role they play in transplantation remains to be elucidated. However, given the potential ability of these cells to modulate antibody responses to allo-antigens, there is great interest in exploring translational applications in situations where B cell responses need to be regulated. Here, we review the current knowledge of Tfr and the role they play focusing on human diseases and transplantation. We also discuss the potential future applications of Tfr therapy in transplantation and examine the evidence for a role of Tfr in antibody production, acute and chronic rejection and tertiary lymphoid organs. Furthermore, the potential impact of immunosuppression on Tfr will be explored. Based on preclinical research, we will analyse the rationale of Tfr therapy in solid organ transplantation and summarize the different challenges to be overcome before Tfr therapy can be implemented into clinical practice. Frontiers Media S.A. 2021-02-02 /pmc/articles/PMC7884443/ /pubmed/33603742 http://dx.doi.org/10.3389/fimmu.2020.612848 Text en Copyright © 2021 Dudreuilh, Basu, Scottà, Dorling and Lombardi http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Dudreuilh, Caroline
Basu, Sumoyee
Scottà, Cristiano
Dorling, Anthony
Lombardi, Giovanna
Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation
title Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation
title_full Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation
title_fullStr Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation
title_full_unstemmed Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation
title_short Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation
title_sort potential application of t-follicular regulatory cell therapy in transplantation
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884443/
https://www.ncbi.nlm.nih.gov/pubmed/33603742
http://dx.doi.org/10.3389/fimmu.2020.612848
work_keys_str_mv AT dudreuilhcaroline potentialapplicationoftfollicularregulatorycelltherapyintransplantation
AT basusumoyee potentialapplicationoftfollicularregulatorycelltherapyintransplantation
AT scottacristiano potentialapplicationoftfollicularregulatorycelltherapyintransplantation
AT dorlinganthony potentialapplicationoftfollicularregulatorycelltherapyintransplantation
AT lombardigiovanna potentialapplicationoftfollicularregulatorycelltherapyintransplantation